ARKG
Not rated
No published distribution safety rating is available.
ETF Comparison
ARKG vs HLTH vs XLV: Which Fits Each Goal in 2026?
A side-by-side comparison of ARK Genomic Revolution ETF, Tema Healthcare AI ETF and State Street Health Care Select Sector SPDR ETF covering yield, cost, risk, and income potential.
Updated November 6, 2026
No track record yet. HLTH launched within the last six months. The forward distribution rate is left blank until a payout is published.
How these figures are calculated: methodology.
Price and total return
Compare the same available dates. Add a ticker or benchmark below; these controls change the chart only. The snapshot and article describe the original comparison.
Interactive history loads here. The snapshot and period returns remain available when chart history cannot be loaded.
Distribution Safety Score
An estimate of distribution reliability, not price or principal safety, a probability, or a guarantee. Score methodology.
HLTH
Not rated
No published distribution safety rating is available.
XLV
Safe
High confidence
Score snapshot as of . Method 1.11.
Side-by-side snapshot
| Metric |  ARKG |  HLTH |  XLV |
|---|---|---|---|
| Full name | ARK Genomic Revolution ETF | Tema Healthcare AI ETF | State Street Health Care Select Sector SPDR ETF |
| Issuer | ARK Invest | Tema ETFs | State Street |
| Last Close | $45.45 as of November 6, 2026 | $26.95 as of November 6, 2026 | $184.80 as of November 6, 2026 |
| Distribution rate | — | — | 1.39% |
| Trailing 12-month yield | — | — | 1.38% |
| Distribution Safety Score™ | — | — | 100 |
| Safety-Adjusted Yield | — | — | 1.39% |
| Expense ratio | 0.75% | 0.75% | 0.08% |
| AUM | $2.15B | $11.7M | $49.1B |
| Distribution frequency | None | None | Quarterly |
| Underlying index | Actively managed (no tracked index recorded) | Actively managed (no tracked index recorded) | Health Care Select Sector Index |
| Objective | Actively managed ETF focused on companies in genomics, gene editing, CRISPR, and molecular diagnostics. | Seeks long-term capital appreciation through an actively managed portfolio of companies applying artificial intelligence across healthcare — including AI-driven drug discovery, diagnostics, medical imaging, medical devices, and healthcare IT platforms. | Provide exposure to the fund's underlying index or strategy per issuer materials. |
| Asset class | Equity | Equity | Equity |
| Inception date | 10/31/2014 | 07/21/2026 | 12/16/1998 |
| Beta | 2.21 | — | 0.41 |
| Last dividend | — | — | $0.642 |
| Ex-dividend date | 12/29/2021 | — | 09/21/2026 |
— Distribution rate, Safety-Adjusted Yield, last dividend, and ex-dividend date are not yet available because HLTH launched July 2026; these fields will populate after the first distribution.
Total returns
100% reinvested · ex-date convention. Period returns use this fixed assumption, independent of chart settings. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year.
ARKG tops the group over the year to date with a 54.02% total return, against HLTH at 5.60% and XLV at 20.93%. Figures are total returns: price change plus every distribution reinvested.
| Symbol | YTD cumulative | Since Jul 2026 | Volatility | Sharpe | Sortino | Max drawdown |
|---|---|---|---|---|---|---|
| ARKG | 54.02% | 12.79% | 54.9% | 0.65 | 0.93 | -21.4% |
| HLTH | 5.60% | 5.60% | 35.9% | 0.39 | 0.52 | -12.6% |
| XLV | 20.93% | 15.83% | 18.4% | 2.43 | 4.21 | -5.9% |
Total return with all distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date), split-adjusted, as of November 5, 2026. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year. “Since Jul 2026” measures every fund from July 21, 2026 — the start of shared available history — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the shared window since Jul 2026. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the shared window since Jul 2026) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Not a distribution payer
ARKG (ARK Genomic Revolution ETF) has no distribution rate on file and its distribution frequency is None. ARKG is not a payer. The blank yield is not a zero yield. HLTH (Tema Healthcare AI ETF) has no distribution rate on file and its distribution frequency is None. HLTH is not a payer. The blank yield is not a zero yield.
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Income calculator
See how much monthly income a hypothetical investment would generate in each ETF at current yields.
ETFs14
Total AUM$15.5B
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
ARK Invest is known for actively managed ETFs focused on disruptive innovation and emerging technologies across digital assets and innovation themes. ARK's funds are characterized by concentrated portfolios of high-conviction stock picks and a research-driven approach to identifying companies positioned to benefit from technological transformation.
See our curated list of related YouTube videos on ARKG.
ETFs15
Total AUM$4.23B
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
Tema ETFs is known for offering thematically focused and income-oriented strategies that target specific industries and trends rather than broad market exposure. The issuer's lineup spans both income-generating funds and thematic investments centered on sectors such as defense, healthcare, technology, and infrastructure, with tickers including ARMY, CANC, DSPY, HLTH, LAZR, NASA, and VOLT. Tema's approach appeals to investors seeking targeted exposure to niche market segments, combining specialized industry focus with dividend and yield strategies.
See our curated list of related YouTube videos on HLTH.
ETFs186
Total AUM$2.15T
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
Their 88-fund lineup spans diverse strategies including sector exposure (Select Sector SPDR), income generation (Income and Select Sector SPDR Premium Income families), commodities (including the widely-held GLD gold ETF), bonds, ESG-focused investments, and thematic allocations, with popular tickers like DIA (Diamonds Trust), FEZ (Eurozone exposure), and JNK (high-yield bonds) among their most recognized funds. The issuer is characterized by its comprehensive coverage across multiple market segments and its emphasis on both traditional index-based products and specialized strategies like covered call income funds and factor-based investing.
See our curated list of related YouTube videos on XLV.
Quick verdict
ARKG (ARK Genomic Revolution ETF), HLTH (Tema Healthcare AI ETF), XLV (State Street Health Care Select Sector SPDR ETF) are ETFs that take different approaches.
XLV reports a 1.39% distribution yield; the others have not yet established a full distribution history.
XLV is the cheapest with an expense ratio of 0.08%, compared to 0.75% for ARKG and 0.75% for HLTH.
XLV has the most assets at $49.1B, but HLTH only launched recently — AUM comparisons will become more meaningful as they build a track record.
Top-holdings overlap
Positions that appear in every fund's top 10. Issuers disclose only the largest weights, so this captures the overlap of the concentrated end of each book — not the full portfolios.
0 shared positions
ARKG 0.0% of its top-10 weight
HLTH 0.0% of its top-10 weight
XLV 0.0% of its top-10 weight
No overlap among the top-10 disclosed holdings of ARKG, HLTH, XLV. These funds draw from largely different positions at the top of their books.
Deep dive
Yield & income
On a $10,000 investment at current distribution rates, ARKG pays no distribution (not a payer; a blank rate is not a zero yield); HLTH pays no distribution (not a payer; a blank rate is not a zero yield); XLV would pay about $139.00 a year (about $34.75 per quarterly distribution).
ARKG yield—
HLTH yield—
XLV yield1.39%
Cost & efficiency
Over 10 years on $10,000: ARKG costs ~$750, HLTH costs ~$750, XLV costs ~$80 in fees (simplified, not compounded).
ARKG ER0.75%
HLTH ER0.75%
XLV ER0.08%
Strategy & risk
ARKG is an actively managed ETF; HLTH is an actively managed ETF built around healthcare exposure; XLV tracks Health Care Select Sector Index with an index approach.
ARKG beta2.21
HLTH beta—
XLV beta0.41
Fund details
ARKG is managed by ARK Invest (launched 10/31/2014) with $2.15B in assets. HLTH is managed by Tema ETFs (launched 07/21/2026) with $11.7M in assets. XLV is managed by State Street (launched 12/16/1998) with $49.1B in assets.
ARKG AUM$2.15B
HLTH AUM$11.7M
XLV AUM$49.1B
Frequently asked questions
Which of ARKG, HLTH, XLV is best for dividend income?
It depends on your goals. XLV currently offers the highest reported distribution yield, which means more income per dollar invested. However, a lower-yield fund may offer better total return or lower volatility, and ARKG and HLTH are not a payer, so a blank yield is not a zero yield. Consider your time horizon and risk tolerance.
What is the difference between ARKG, HLTH, XLV?
ARKG (ARK Genomic Revolution ETF) is an actively managed ETF, issued by ARK Invest. HLTH (Tema Healthcare AI ETF) is an actively managed ETF built around healthcare exposure, issued by Tema ETFs. XLV (State Street Health Care Select Sector SPDR ETF) tracks Health Care Select Sector Index with an index approach, issued by State Street.
Can I hold ARKG, HLTH, XLV together?
Yes. Their disclosed top-10 holdings share no positions, so combining them together spreads your money across different underlying names — see the holdings-overlap section above for the details. Overlap outside the disclosed top 10 can still exist.
Which has the lowest fees among ARKG, HLTH, XLV?
ARKG has an expense ratio of 0.75%, HLTH has an expense ratio of 0.75%, XLV has an expense ratio of 0.08%. Lower fees mean more of your investment returns stay in your pocket over time.
How much income does $10,000 generate in each?
At current distribution rates, $10,000 in ARKG has no distribution to estimate, because ARKG is not a payer and a blank rate is not a zero yield. $10,000 in HLTH has no distribution to estimate, because HLTH is not a payer and a blank rate is not a zero yield. $10,000 in XLV would pay about $139.00 a year (about $34.75 per quarterly distribution).
More comparisons to explore
People also compare ARKG with
People also compare HLTH with
Popular comparisons
Dividend dates and history
ARKG vs HLTH vs XLV — at a glance
Generated November 1, 2026.
Figures quoted in this analysis are from its generation date and may lag the live snapshot table above, which always shows the latest data.
Overview
These three ETFs offer exposure to healthcare but through markedly different lenses: ARKG is an actively managed genomics and gene-editing fund; HLTH is an actively managed AI-in-healthcare strategy; XLV is a passive index fund tracking the entire health-care sector. The real distinction is between narrow, high-growth thematic bets (ARKG and HLTH) and broad sector exposure with income (XLV).
How they differ
ARKG and HLTH are both active strategies targeting futuristic healthcare subsectors—genomics and AI respectively—while XLV tracks the broad health-care index passively. That structural difference produces very different risk and return profiles: ARKG has a beta of 2.21, meaning it swings roughly twice as hard as the market, while XLV's beta of 0.52 suggests it moves less than half as much. On cost, XLV's 0.08% fee is a 67-basis-point advantage over ARKG's 0.75%, though both active funds match at 0.75%.
Who each is best for
ARKG: Fits investors with a long time horizon and appetite for volatility who believe genomic and gene-editing innovation will outpace the broader market—willing to hold through deep drawdowns for potential outsized gains.
HLTH: Designed for growth-oriented investors convinced AI-driven medical breakthroughs will reshape healthcare, with the caveat that the fund is newly established and its track record is nonexistent; best suited to those who can tolerate tracking-error risk and want AI exposure within healthcare specifically.
XLV: Suits investors seeking steady exposure to established health-care names with quarterly income, a predictable beta closer to the broader market, and minimal fees—those prioritizing capital preservation and yield over growth or thematic conviction.
Key risks to know
- Concentration and theme risk: ARKG's focus on genomics and gene editing means the portfolio rises or falls with CRISPR adoption, regulatory approval timelines, and biotech sentiment; a shift in investor appetite for genetic-therapy stocks could trigger significant NAV swings regardless of company fundamentals.
- High volatility without diversification: ARKG's beta of 2.21 paired with active sector betting means the fund can decline sharply in corrections; investors uncomfortable with 40%+ drawdowns should be cautious regardless of the genomics thesis.
- Valuation and regulatory risk: Both ARKG and HLTH bet heavily on companies with speculative business models and unproven drug pipelines; FDA decisions, clinical trial failures, and reimbursement policy shifts can wipe out gains overnight.
- Index exposure drift: XLV's broad health-care index exposure means it will underperform if cutting-edge genomics and AI—the fastest-growing subsectors—significantly outpace legacy pharmaceutical and medical-device players over a multi-year horizon. If you value sector breadth, steady 1.39% income, and 0.08% fees, XLV is the conservative baseline. Past performance does not guarantee future results, and thematic ETFs' concentrated bets often underperform broad indices over long periods.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Learn the method
The metrics behind this comparison, explained in the Academy.
These comparisons follow the Dividend Vision methodology.